# The research record — bremelanotide mechanism and clinical trials > The bremelanotide research record: MC4R-mediated central mechanism, the Pfaus rat-solicitation study, the male intranasal detour, the RECONNECT Phase 3 reads, and the 2024 PDE5i co-formulation Phase 2. Three acts and an active third: a preclinical rat-solicitation paper, a male-intranasal detour that bent the program, and the pivotal Phase 3 reads that produced an FDA approval in 2019. ## Before the science In plain words, the PT-141 research divides into two threads. The first is mechanism: the drug acts on melanocortin receptors in the hypothalamus, not on blood vessels, and a string of animal and human studies points the same direction. A 2022 brain-imaging study in 31 women with HSDD showed that MC4R agonism raised desire for up to 24 hours and changed how the brain processed erotic stimuli — the strongest direct evidence that the effect is central rather than vascular. The second thread is outcomes: what happened when it was given to people. The strongest data sit in two matched Phase 3 trials in premenopausal women with distressing low desire, the only approved use. There is also an older line of work in men with erectile dysfunction that never reached approval, and an active 2024 Phase 2 program revisiting that question. Below, the mechanism comes first, then the human trials, then the honest caveats — including critics who argue the measured benefit is small. Every number traces to the bibliography. ## Still I. The central mechanism The receptor profile is the foundation. Bremelanotide is a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with high nanomolar affinity at MC3R and MC4R, moderate affinity at MC1R, very low affinity at MC5R, and essentially no activity at MC2R [1][2]. The MC2R-sparing profile matters clinically — MC2R is the adrenocortical ACTH receptor, and a melanocortin agonist that engaged it would risk corticosteroid release. Bremelanotide does not. The therapeutic effect on sexual desire is attributed to MC4R activation in the central nervous system. Following a subcutaneous dose, the drug reaches MC4R-expressing neurons in the hypothalamus — paraventricular nucleus and medial preoptic area — where it triggers a Gs-adenylyl-cyclase-cAMP-PKA cascade with secondary Gq coupling and ERK1/2 MAPK activation [2]. The downstream consequence is dopamine release in the mesolimbic reward circuit (ventral tegmental area to nucleus accumbens) and oxytocin release from PVN magnocellular neurons. MC4R knockout abolishes the proceptive behavioral phenotype, which is the strongest single line of evidence that MC4R is the obligate receptor [11]. The 2022 CNS Spectrums neurobiology review synthesizes fMRI, lesion, and receptor-localization data into a single working model: MC4R activation in the PVN drives oxytocin release; MC3R/MC4R activation in the VTA and nucleus accumbens shell engages dopaminergic reward; engagement of the MPOA integrates proceptive motor and motivational output [12]. That tripartite axis — hypothalamus, reward circuit, motor-motivational gate — is the proposed neural substrate for the clinical effect. ## Still II. The rat study that started it Behavioral evidence preceded the human program by roughly fifteen years. The 2004 Pfaus paper in Proceedings of the National Academy of Sciences administered bremelanotide subcutaneously to female Long-Evans rats at 100 and 200 micrograms per kilogram and observed a selective increase in sexual solicitation — the appetitive partner-seeking behaviors — without changes in lordosis, hops and darts, pacing, or measures of sexual reward perception [3]. The selectivity was the point. A drug that produced general arousal or motor activation would have moved everything. Bremelanotide moved only proceptive behavior. That dissociation pointed the central melanocortin system at a specific behavioral construct — desire, not performance — and gave the eventual female HSDD program its mechanistic rationale [3]. A 2007 preclinical review extended this across rodent species and confirmed MC4R as the receptor doing the work [11]. ## Still III. The male intranasal detour Before bremelanotide became a women's-health drug, the developer ran it as a male erectile-dysfunction candidate via the intranasal route. A 2004 dose-ranging study in healthy men and men with mild-to-moderate ED found a statistically significant erectogenic response at intranasal doses at or above 7 mg, with first erection onset around 30 minutes post-dose [7]. A 2005 paper added that low-dose intranasal bremelanotide (7.5 mg) combined with a sub-therapeutic dose of a PDE5 inhibitor produced an enhanced erectile response versus either agent alone — the first human evidence that central melanocortin agonism and peripheral PDE5 inhibition could act additively [9]. A 2008 trial in PDE5-inhibitor non-responders extended that finding [20]. The intranasal program was halted. Dose-related transient elevations in blood pressure were more pronounced via the intranasal route than via subcutaneous administration, and at supratherapeutic doses they crossed thresholds that triggered a clinical hold [7]. A parallel subcutaneous-route study in healthy men and PDE5i-inadequate ED demonstrated an erectogenic response with a more favorable cardiovascular profile, which is what shifted the entire program to subcutaneous delivery [8]. The intranasal chapter is closed; the subcutaneous route became the path for everything after. ## Still IV. The Phase 2b dose finding The dose that eventually appeared on the label was selected in a Phase 2b dose-finding trial in premenopausal women with female sexual dysfunction. The trial compared subcutaneous bremelanotide at 0.75, 1.25, and 1.75 mg against placebo. The 1.75 mg arm produced the most consistent statistically significant improvements in FSFI total and desire-domain scores and in distress scales, and it was the dose advanced to Phase 3 [10]. The Phase 3 program — RECONNECT — was built on that selection. ## Still V. RECONNECT — the pivotal Phase 3 read RECONNECT was two identically designed, randomized, placebo-controlled, 24-week Phase 3 trials enrolling premenopausal women with acquired, generalized HSDD. Pooled, the program randomized 1,247 women. Subcutaneous bremelanotide 1.75 mg on demand — with a strict maximum of one dose per 24 hours and eight doses per month — produced statistically significant improvements on both co-primary endpoints versus placebo [4]. The FSFI Desire domain rose by 0.35 units on bremelanotide versus 0.21 on placebo; the FSDS-DAO-13 distress item fell by 0.74 units versus 0.42 [4]. Both endpoints reported p<0.001 in pooled analysis. A prespecified, integrated 2022 subgroup analysis (n=1,202 integrated) found the treatment effect held across age (18–39 versus 40 and above), BMI (below versus at-or-above 30), hormonal contraceptive use, and HSDD duration (below versus at-or-above five years) [6]. The 52-week open-label extension carried 684 of 856 eligible patients into year one; 272 completed the full extension; nausea (40.4%), flushing (20.6%), and headache (12.0%) were the most common treatment-related adverse events, with no new safety signals identified [5]. The satisfying-sexual-events endpoint did not separate from placebo in pooled analyses [4]. That divergence — strong subjective endpoints, flat behavioral count — became the principal methodological argument around the 2019 approval and remains a live question in the HSDD outcome-measurement literature. ## Still VI. The 2024 second season The developer reopened the male erectile-dysfunction question in 2024, this time with a subcutaneous co-formulation. The Phase 2 open-label dose-escalation study (approximately 50 men) of a single combined subcutaneous injection containing bremelanotide and a PDE5 inhibitor was initiated for men whose ED is inadequately responsive to PDE5 inhibitor monotherapy — the same population first hinted at by the 2005 Diamond additive-effect data [18][9]. Topline data were targeted for the end of calendar 2024, with a Phase 3 program planned for the first half of 2025. A parallel 2024 lactation pharmacokinetic study (NCT06867835) was launched to quantify bremelanotide concentrations in human breast milk after a single subcutaneous dose in lactating women, addressing a labeling gap relevant to postpartum HSDD management [19]. And a 2025 expert review in Expert Review of Clinical Pharmacology discusses bremelanotide as a non-hormonal, centrally acting libido option for breast-cancer patients on endocrine therapies who cannot use systemic estrogens — the first formal positioning of the drug in oncology survivorship pharmacology [17]. The third act is in progress. --- An indexed dossier of peer-reviewed bremelanotide research — not a clinic, not a vendor, nothing prescribed or dispensed here.